skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.05e (Release date: 2017-05-30)
SearchBox Top
SearchBox Bottom
ADE Regimen (Code C9579)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: ADE Regimen

Definition: A regimen consisting of cytarabine (Ara-C), daunorubicin and etoposide, that is used as an induction treatment for pediatric acute myeloid leukemia (AML).

NCI-GLOSS Definition: An abbreviation for a chemotherapy combination used to treat childhood acute myeloid leukemia (AML). It includes the drugs cytarabine (Ara-C), daunorubicin hydrochloride, and etoposide phosphate.

Label: ADE Regimen

NCI Thesaurus Code: C9579 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0057163  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
ADE regimen
ADE Regimen
AraC-Daunorubicin-Etoposide Regimen
Cytarabine-Daunorubicin-Etoposide Regimen
MRC AML10 Study-ADE Regimen

External Source Codes: 
PDQ Closed Trial Search ID 656988
PDQ Open Trial Search ID 656988 (check for NCI PDQ open clinical trial info)
UMLS CUI C0057163

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Acute Myeloid Leukemia
code C9579
Legacy_Concept_Name Cytarabine_Daunorubicin_Etoposide
Semantic_Type Therapeutic or Preventive Procedure

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom